socalTECH

JUNE 3, 2020

San Diego-based Evofem Biosciences , a publicly held, biopharmaceuticals company which is developing products in the area of women's sexual and reproductive health, says it has priced approximately $100M in common stock to the public. Evofem had its IPO back in 2018. Wainwright & Co. READ MORE>>.

San Diego 113

San Diego Pricing Product Develop 113

Xconomy

JULY 31, 2020

Bain Capital and Pfizer (NYSE: PFE ) launched it in 2018 with neuroscience compounds from the pharma giant’s labs. If you’ve never heard of Arya (NASDAQ: ARYBU ), it’s a shell company that Perceptive Advisors formed specifically to serve as a vehicle to take a private company public. Cerevel is young, but it’s pretty far along.

Pricing 72

Pricing Acquisition Capital Marketing 72

Xconomy

MAY 9, 2019

Five biotechs priced their IPOs and at least one more is coming. According to IPO research firm Renaissance Capital , 47 IPOs have priced so far this year across all sectors, down 27 percent compared to the same period in 2018. Just as last year, healthcare IPOs lead the way.

Pricing 110

Pricing Research Capital Marketing 110

Xconomy

DECEMBER 21, 2018

Before you fly off, or drive, or simply unplug, check out our preview of what could be next year’s top clinical studies; the tumult in big pharma’s on again-off again relationship with consumer healthcare; big names on the move in the nation’s capital; and a flurry of year-end deals. Happy holidays, everyone.

Pricing 73

Pricing Sales Study News 73

Xconomy

APRIL 23, 2019

After a breakout year in 2017, the blockchain sector suffered a series of blows in 2018, from crashing cryptocurrency prices to increased regulatory scrutiny of crypto ventures and deepening skepticism about whether the technology was actually useful.

Report 98

Report Pricing Organization Technology 98

Xconomy

JULY 19, 2019

Soaring prices of Bitcoin and other so-called digital tokens were attracting investments from speculators hoping to get rich quick—but these virtual coin values were also known to drop just as suddenly, the US Treasury Department’s Financial Stability Oversight Council noted.

Pricing 89

Pricing Report Invest Venture Capital 89

Xconomy

JANUARY 4, 2019

In 2018, my Exome colleagues and I published hundreds of stories about health, medicine, the biopharma industry, government policy, and more. Topics ranged from the worries over CRISPR genome editing and Wild West biohacking, to Nobel Prize-fueled drug approvals and the headaches around drug prices (even for drugs meant to cure headaches).

Pricing 69

Pricing Email Networking Silver Lake 69